US20020013332A1 - Use of nicergoline for treating spasticity - Google Patents

Use of nicergoline for treating spasticity Download PDF

Info

Publication number
US20020013332A1
US20020013332A1 US09/863,787 US86378701A US2002013332A1 US 20020013332 A1 US20020013332 A1 US 20020013332A1 US 86378701 A US86378701 A US 86378701A US 2002013332 A1 US2002013332 A1 US 2002013332A1
Authority
US
United States
Prior art keywords
nicergoline
mg
spasticity
riluzole
pyramidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/863,787
Other versions
US6380208B2 (en
Inventor
Michel Dib
Vincent Meininger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9814794A priority Critical patent/FR2786101B1/en
Priority to FR9814794 priority
Priority to PCT/FR1999/002866 priority patent/WO2000030642A1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Assigned to AVENTIS PHARMA S.A. reassignment AVENTIS PHARMA S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DIB, MICHEL, MEININGER, VINCENT
Publication of US20020013332A1 publication Critical patent/US20020013332A1/en
Publication of US6380208B2 publication Critical patent/US6380208B2/en
Application granted granted Critical
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/465The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio

Abstract

The invention concerns the use of nicergoline for treating pyramidal spasticity of neurological diseases involving a pathology of the cerebrospinal tract.

Description

  • This application is a continuation of International application No. PCT/FR99/02,866, filed Nov. 22, 1999; which claims the benefit of priority of French Patent Application No. 98/14,794, filed Nov. 24, 1998. [0001]
  • The present invention relates to the use of nicergoline in the treatment of the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway. [0002]
  • Spasticity is among the clinical traits of neurological diseases which have in common an attack of the pyramidal pathway, such as, for example, amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis and cerebrovascular accidents. [0003]
  • Nicergoline, or (8β)-10-methoxy-1,6-dimethylergoline-8-methanol-5-bromonicotinate (Sermion®), in particular has α-blocking and α2-adrenolytic properties (CARPENE C. et al., J. Pharmacol, 14, 57-66 (1983)), anti-ischemic properties (CAHN R. et al., Chem. Abstracts, 107, 228784x (1987); UEDAT et al., Chem. Abstracts, 118, 225224f (1993)), anti-calcium properties (TAKAHASHI K. et al., Br. J. Pharmacol., 100, 705-710 (1990)), antioxidant properties (TANAKA M. et al., Neurosci. Let., 248, 67-72 (1998)) and antithrombotic properties (Chem. Abstracts 105, 54314k (1986)). It improves the memory and the learning capacity (Chem. Abstracts, 113, 52358u (1990); Chem. Abstracts, 111, 108396h, 1989; Chem. Abstracts, 109, 86208c, 1988; Chem. Abstracts, 106, 12788e, 1987; Chem. Abstracts, 115, 198237s, 1991). [0004]
  • It has now been found that nicergoline reduces the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway and, in particular, of the spasticity during amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis and cerebrovascular accidents. [0005]
  • Amyotrophic lateral sclerosis (ALS), also known as Charcot's disease and Lou Gehrig's disease, was described for the first time by Charcot in 1865. ALS is a fatal disease resulting from degeneration of the motor neurones. The disease is accompanied by a progressive paralysis, leading to the loss of the motor and respiratory functions and then to death within a period of two to eight years from the appearance of the first symptoms. [0006]
  • Stiffness is among the characteristic clinical traits of this condition. Its degree is variable and it is common to find that there are very stiff patients opposite patients who have little or no stiffness. [0007]
  • This stiffness is generally related to hypertonia (or contracture or spasticity) of the pyramidal syndrome and it is common to consider it as being due to the exclusive attack of the pyramidal pathway. [0008]
  • Clinically, however, it is not always easy to relate the stiffness observed to pyramidal attack alone. [0009]
  • The reason for this is that it is necessary to distinguish between pyramidal stiffness (or contracture or spasticity) and extrapyramidal stiffness (or rigidity). [0010]
  • Pyramidal contracture (increase in the motor tonus, known as Ch. Foix tendon reflexes) is clinically elastic, it becomes reinforced as the muscular insertion points become separated and it is exaggerated with the speed of movement of the limb and gives the mobilized limb a primitive attitude. It predominates on the flexors in the upper limbs and on the extensors in the lower limbs, with a predominance on the distal muscles. [0011]
  • Extrapyramidal rigidity (exaggeration of the Ch. Foix “posturereflex” plastic tonus), on the other hand, is a sensation of waxy elastic resistance, which is attenuated by repeated gentle passive mobilization. It affects all muscles, predominantly the proximal (rhizomelic) muscles. The tonus of the limbs is exaggerated during passive shortening of the muscle defining the over excitation of the Ch. Foix posture reflexes (Strümpell's fixing rigidity). It tends to fix the limb in the position in which the observer has set it. In this respect, it is similar to phenomena of catatonia and catalepsy. [0012]
  • Finally, these changes in tonus should be combined with oppositional rigidity or Gegenhalten's rigidity which more reflects a frontal attack. It is similar to extrapyramidal rigidity, but differs therefrom by its fluctuating nature and by its exaggeration when the patient attempts to relax. [0013]
  • A certain amount of data argues in favor of attack of the extrapyramidal system in patients suffering from ALS. [0014]
  • In addition to the known association of ALS and Parkinson's disease (in particular in Guam's anatomo-clinical complex), various anatomo-clinical studies have objectivized an attack of the central grey matter. As early as 1925, I. Bertrand and L. Van Bogaert (Rev. Neurol., 32, 779-806 (12925)) reported a diffuse attack of the cerebral cortex and of the central grey matter in patients suffering from ALS. In 1972, P. Castaigne et al. (Rev. Neurol., 127, 401-414 (1972)) noted an attack of the central grey matter in 16 out of 19 “atypical” cases of ALS, although there did not appear to be any clinical extrapyramidal signs in these patients. Isolated cases of ALS with attack of the substantia nigra have also been reported (S. M. Chou, Dekker pub. pp. 133-181 (1992)). By means of a PET scan with 6-fluorodopa, Takahashi et al. (J. Neural. Transm., 5, 17-26 (1993)) showed a decrease in the uptake of fluorodopa in all patients, despite the absence of a clear clinical sign of attack of the extrapyramidal system. This decrease appears to be accentuated gradually over time in the course of the disease. [0015]
  • Clinical experience shows that most stiff patients have a mixed stiffness: pyramidal and extrapyramidal. An important argument in favor of a probably mixed origin of the stiffness observed in patients suffering from ALS is that this symptom is inaccessible or relatively inaccessible to the muscular relaxant treatments usually used in pyramidal spasticity (baclofen, benzodiazepines and dantrolene). [0016]
  • The distinction between rigidity and spasticity is not only of descriptive importance, but is also of importance in the treatment of these patients. The reason for this is that stiffness is a factor that is probably “favorable” in the vital prognosis, but definitely “unfavorable” in the functional prognosis since it is inaccessible or relatively inaccessible to the usual muscular relaxants, even at the price of a considerable increase in doses (occasionally 180 mg/day of baclofen). [0017]
  • A descriptive study on 9 patients suffering from ALS was carried out. The main criterion defined is the stiffness, measured using a visual analog scale (VAS), of 100 mm, or the individual rates by self-assessment the severity of the stiffness perceived. [0018]
  • To date, only riluzole (2-amino-6-trifluoromethoxybenzothiazole) is sold, under the name Rilutek®, for the treatment of amyotrophic lateral sclerosis. Riluzole mainly makes it possible to slow down the progression of the disease, but has no effect on the spasticity. [0019]
  • The patients receive 100 mg/day of riluzole and 15 mg IV of nicergoline on the first day and 30 mg IV on the next 4 days. The duration of infusion was more than 4 hours to avoid any risk of hypotension. [0020]
  • The measurement was carried out before and after administration of nicergoline. [0021]
  • The results are as follows (mean±standard deviation, in mm): [0022]
  • The stiffness before administration of nicergoline is 67.33±25. [0023]
  • The stiffness 4 days later (from 4 to 8 d) is 48.11±19. [0024]
  • The intra-individual difference is 19.22±20.5 (95% I=3.44+35; range=−8 to +57). [0025]
  • The comparison at a zero difference is significant (t=2.809; p (2α)=0.0229). [0026]
  • The test of deviation from a normal distribution is non-significant.[0027]
  • The present application also relates to the combination of riluzole or a pharmaceutically acceptable salt of riluzole and of nicergoline, and to its use in the treatment of the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway and, in particular, of spasticity during amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis and cerebrovascular accidents. [0028]
  • The nicergoline may be prepared according to U.S. Pat. No. 3,228,943. [0029]
  • The riluzole may be prepared according to the process disclosed in EP Patent No. 50551. [0030]
  • Pharmaceutically acceptable salts of riluzole which may be mentioned in particular include the addition salts with mineral acids such as hydrochloride, sulfate, nitrate or phosphate, or with organic acids such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillineacetate, salicylate, phenolphthalinate and methylenebis-β-oxynaphthoate, or substitution derivatives of these derivatives. [0031]
  • The nicergoline may be used orally, parenterally or rectally. [0032]
  • The combination of nicergoline and riluzole may be used orally, parenterally or rectally, either simultaneously or separately or sequentially over time. [0033]
  • The present invention also relates to pharmaceutical compositions comprising nicergoline in pure form or in the form of a combination with one or more compatible and pharmaceutically acceptable diluents and/or adjuvants and/or optionally in combination with another pharmaceutically compatible and physiologically active product and optionally in combination with riluzole or a pharmaceutically acceptable salt thereof. [0034]
  • Solid compositions for oral administration which may be used include tablets, pills, powders (gelatin capsules or cachets) and granules. In these compositions, the active principles are mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon. These compositions may also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a colorant, a coating (sugar coating) or a varnish. [0035]
  • Liquid compositions for oral administration which may be used include pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, plant oils or liquid paraffin. These compositions may comprise substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products. [0036]
  • The sterile compositions for parenteral administration may preferably be aqueous or non-aqueous solutions, suspensions or emulsions. Solvents or vehicles which may be used include water, propylene glycol, a polyethylene glycol, plant oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents. These compositions may also contain adjuvants, in particular wetting agents, isotonic agents, emulsifiers, dispersants and stabilizers. The sterilization may be carried out in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the compositions, by irradiation or by heating. They may also be prepared in the form of sterile solid compositions which may be dissolved at the time of use in sterile water or any other injectable sterile medium. [0037]
  • The compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols. [0038]
  • The present invention also relates to the use of nicergoline either alone or in combination with riluzole or a pharmaceutically acceptable salt thereof, for the preparation of medicinal products that are useful in the treatment of the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway, and in particular of amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis and cerebrovascular accidents. [0039]
  • The present invention also relates to the method for treating the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway, and in particular of amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis and cerebrovascular accidents, which consists in administering to the patient nicergoline or a combination of nicergoline and riluzole or a pharmaceutically acceptable salt thereof, either simultaneously or separately or sequentially over time. [0040]
  • The doses depend on the desired effect, the duration of the treatment and the route of administration used; they are generally from 15 to 30 mg per day orally for an adult, with unit doses of from 5 to 10 mg of nicergoline. [0041]
  • When the combination of nicergoline and riluzole is used, the doses are generally from 10 to 400 mg per day orally for an adult, with unit doses ranging from 10 to 200 mg of riluzole and from 15 to 30mg per day orally for an adult, with unit doses of from 5 to 10 mg of nicergoline. [0042]
  • In general, the doctor will determine the appropriate dosage depending on the age and weight and all the other factors specific to the individual to be treated. [0043]

Claims (20)

1. A method for the treatment of the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition consisting of nicergoline, optionally in combination with a pharmaceutically acceptable carrier.
2. The method as claimed in claim 1 in which the spasticity of the neurological diseases involving an attack of the pyramidal pathway is the spasticity of amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis or cerebrovascular accidents.
3. The method as claimed in claim 1 in which nicergoline is in combination with riluzole or a pharmaceutically acceptable salt thereof.
4. The method as claimed in claim 2 in which nicergoline is in combination with riluzole or a pharmaceutically acceptable salt thereof.
5. The method as claimed in claim 1 wherein the pharmaceutical composition contains 5 to 10 mg of nicergoline.
6. The method as claimed in claim 2 wherein the pharmaceutical composition contains 5 to 10 mg of nicergoline.
7. The method as claimed in claim 3 wherein the pharmaceutical composition contains 5 to 10 mg of nicergoline and 10 to 200 mg of riluzole.
8. The method as claimed in claim 4 wherein the pharmaceutical composition contains 5 to 10 mg of nicergoline and 10 to 200 mg of riluzole.
9. A pharmaceutical composition comprising nicergoline, optionally in combination with a pharmaceutically acceptable carrier, useful in the treatment of the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway.
10. The composition as claimed in claim 9 in which the spasticity of the neurological diseases involving an attack of the pyramidal pathway is the spasticity of amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis or cerebrovascular accidents.
11. The composition as claimed in claim 9 in which nicergoline is in combination with riluzole or a pharmaceutically acceptable salt thereof.
12. The composition as claimed in claim 10 in which nicergoline is in combination with riluzole or a pharmaceutically acceptable salt thereof.
13. The composition as claimed in claim 9 which contains 5 to 10 mg of nicergoline.
14. The composition as claimed in claim 10 which contains 5 to 10 mg of nicergoline.
15. The composition as claimed in claim 11 which contains 5 to 10 mg of nicergoline and 10 to 200 mg of riluzole.
16. The composition as claimed in claim 12 which contains 5 to 10 mg of nicergoline and 10 to 200 mg of riluzole.
17. A pharmaceutical composition comprising a combination of nicergoline and riluzole or a pharmaceutically acceptable salt thereof.
18. The composition as claimed in claim 17, as a combined preparation for simultaneous, separate or sequential use.
19. The composition as claimed in claim 17 useful in the treatment of the pyramidal spasticity of neurological diseases involving an attack of the pyramidal pathway.
20. The composition as claimed in claim 19 in which the spasticity of the neurological diseases involving an attack of the pyramidal pathway is the spasticity of amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy, primary lateral sclerosis or cerebrovascular accidents.
US09/863,787 1998-11-24 2001-05-23 Use of nicergoline for treating spasticity Active US6380208B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9814794A FR2786101B1 (en) 1998-11-24 1998-11-24 Use of nicergoline for the treatment of spasticity
FR9814794 1998-11-24
PCT/FR1999/002866 WO2000030642A1 (en) 1998-11-24 1999-11-22 Use of nicergoline for treating spasmodism

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/059,869 US6713493B2 (en) 1998-11-24 2002-01-29 Use of nicergoline in the treatment of spasticity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/002866 Continuation WO2000030642A1 (en) 1998-11-24 1999-11-22 Use of nicergoline for treating spasmodism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/059,869 Division US6713493B2 (en) 1998-11-24 2002-01-29 Use of nicergoline in the treatment of spasticity

Publications (2)

Publication Number Publication Date
US20020013332A1 true US20020013332A1 (en) 2002-01-31
US6380208B2 US6380208B2 (en) 2002-04-30

Family

ID=9533131

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/863,787 Active US6380208B2 (en) 1998-11-24 2001-05-23 Use of nicergoline for treating spasticity
US10/059,869 Active 2019-12-08 US6713493B2 (en) 1998-11-24 2002-01-29 Use of nicergoline in the treatment of spasticity

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/059,869 Active 2019-12-08 US6713493B2 (en) 1998-11-24 2002-01-29 Use of nicergoline in the treatment of spasticity

Country Status (11)

Country Link
US (2) US6380208B2 (en)
EP (1) EP1133295B1 (en)
JP (1) JP4936594B2 (en)
AT (1) AT248596T (en)
AU (1) AU1278500A (en)
DE (1) DE69911052T2 (en)
DK (1) DK1133295T3 (en)
ES (1) ES2201801T3 (en)
FR (1) FR2786101B1 (en)
PT (1) PT1133295E (en)
WO (1) WO2000030642A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469019B2 (en) * 1998-11-24 2002-10-22 Aventis Pharma S.A. Therapeutic application of nicergoline
US20040028723A1 (en) * 2000-08-24 2004-02-12 Reinhard Horowski Transdermal therapeutic system for treating restless-legs-syndrome
US20040219191A1 (en) * 2000-12-16 2004-11-04 Karsten Kuhn Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means
US20050214353A1 (en) * 2000-10-20 2005-09-29 Reinhard Horowski Transdermal therapeutic system

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (en) * 1998-11-24 2002-07-05 Aventis Laboratoire Use of nicergoline for the treatment of spasticity
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2801793B1 (en) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association of ergoline and riluzole and its use as a drug

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228943A (en) 1966-01-11 Lumilysergol derivatives
YU39278B (en) * 1976-12-22 1984-10-31 Lek Tovarna Farmacevtskih Process for preparing 5-bromo nicotinic acid esters
FR2492258B1 (en) 1980-10-17 1982-11-26 Pharmindustrie
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IT1252163B (en) * 1991-12-03 1995-06-05 Poli Ind Chimica Spa Pharmaceutical compositions for neuroprotection in neurological diseases of degenerative or ischemic
JP2864885B2 (en) * 1992-07-02 1999-03-08 田辺製薬株式会社 Nicergoline containing oral preparation
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
IT1256743B (en) * 1992-12-18 1995-12-15 Giorgio Pifferi Pharmaceutical compositions with controlled release containing nicergoline
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
FR2777781B1 (en) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Riluzole Associations and l-dopa for the treatment of Parkinson's disease
DE19842416A1 (en) * 1998-09-16 2000-04-13 Max Planck Gesellschaft Secondary amines for the prevention and treatment of diseases caused by oxidation processes or enhanced
FR2785808B1 (en) * 1998-11-13 2002-12-06 Aventis Laboratoire riluzole and alpha-tocopherol
FR2786099B1 (en) * 1998-11-24 2000-12-29 Aventis Laboratoire New therapeutic application of 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
FR2786101B1 (en) * 1998-11-24 2002-07-05 Aventis Laboratoire Use of nicergoline for the treatment of spasticity
FR2786100B1 (en) * 1998-11-24 2002-03-01 Aventis Laboratoire New therapeutic application of nicergoline
US6297254B1 (en) * 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469019B2 (en) * 1998-11-24 2002-10-22 Aventis Pharma S.A. Therapeutic application of nicergoline
US20040028723A1 (en) * 2000-08-24 2004-02-12 Reinhard Horowski Transdermal therapeutic system for treating restless-legs-syndrome
US20040101550A1 (en) * 2000-08-24 2004-05-27 Fred Windt-Hanke Transdermal therapeutic system
US20050220855A1 (en) * 2000-08-24 2005-10-06 Reinhard Horowski Transdermal therapeutic system
US20050214353A1 (en) * 2000-10-20 2005-09-29 Reinhard Horowski Transdermal therapeutic system
US7258871B2 (en) 2000-10-20 2007-08-21 Neurobiotec Gmbh Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
US20040219191A1 (en) * 2000-12-16 2004-11-04 Karsten Kuhn Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means

Also Published As

Publication number Publication date
WO2000030642A1 (en) 2000-06-02
AU1278500A (en) 2000-06-13
DK1133295T3 (en) 2003-12-22
EP1133295B1 (en) 2003-09-03
US20020086875A1 (en) 2002-07-04
FR2786101A1 (en) 2000-05-26
EP1133295A1 (en) 2001-09-19
PT1133295E (en) 2004-01-30
JP2003530298A (en) 2003-10-14
DE69911052T2 (en) 2004-08-19
DE69911052D1 (en) 2003-10-09
AT248596T (en) 2003-09-15
US6380208B2 (en) 2002-04-30
JP4936594B2 (en) 2012-05-23
US6713493B2 (en) 2004-03-30
ES2201801T3 (en) 2004-03-16
FR2786101B1 (en) 2002-07-05

Similar Documents

Publication Publication Date Title
STEELE et al. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia
Dunbar et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients
Nyth et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
Nyth et al. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders A Nordic multicentre study
CA2483464C (en) Method for treating obesity
CN102065858B (en) Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
Dionne Pharmacologic treatments for temporomandibular disorders
Girotti et al. Dementia and cognitive impairment in Parkinson's disease.
Lieberman et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine
Siris et al. Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial
Sharief et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy
McDougle et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder
Street et al. Long‐term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia
Arnsten et al. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes
Nolen et al. Treatment strategy in depression: II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L‐5‐hydroxytryptophan and nomifensine
Hollander et al. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report
Pillon et al. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
Andersen et al. Anti‐depressive treatment in Parkinson's disease A CONTROLLED TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH L‐DOPA
Johnson et al. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia
Kimonis et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone
Hoehn-Saric et al. Effects of clonidine on anxiety disorders
Gibb et al. Cortical Lewy body dementia: clinical features and classification.
Mendels et al. Double‐blind comparison of citalopram and placebo in depressed outpatients with melancholia
Wojcik et al. A review of 32 cases of tardive dystonia
Hollander et al. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVENTIS PHARMA S.A., FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DIB, MICHEL;MEININGER, VINCENT;REEL/FRAME:011998/0353

Effective date: 20010510

REMI Maintenance fee reminder mailed
SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12